在酗酒治疗试验中，异丁司特疗效不敌安慰剂，但对女性例外

Summary: A UCLA trial found ibudilast, once promising for alcohol use disorder, was no better than placebo overall. But women on it drank less per day, and those with more depression did better on placebo. Results support further study of treatments based on individual traits. Key Facts:

• Mixed Results: Ibudilast didn't outperform placebo generally.
• Gender - Specific: Women improved more on ibudilast; depressed people did better on placebo.
• Placebo Effect: Both groups improved, making efficacy evaluation difficult.

Source: UCLA. A drug once thought to help alcohol use disorder didn't work as hoped. Ibudilast, approved in Japan for other uses, previously seemed to reduce drinking. The study in JAMA Network Open showed it was no more effective than placebo for most, but had a positive effect on women. Lara Ray said some did better and some worse on the drug. Women participants improved, but those with more depression did worse. The UCLA Addictions Lab's years - long study of ibudilast shows inflammation and the immune system may play roles in alcoholism. For the study, 102 adults with alcohol use disorder took either ibudilast or placebo for 12 weeks and were followed for 4 weeks after. They tracked drinking and depressive symptoms. Both groups reduced drinking. Average drinks per day dropped from seven to three or four. But this was in both groups, so ibudilast wasn't proven better. A challenge is all participants usually improve. Women on ibudilast drank fewer drinks per day. People with more depressive symptoms did better on placebo. Ray said the lab is uncovering new treatments. Future challenges include longer follow - up. Analyses will help figure out who responds to the drug. The trial was funded by the National Institute on Alcohol Abuse and Alcoholism.

The neuroimmune system is a target for AUD medications. Ibudilast is a neuroimmune modulator. A randomized, double - masked, phase 2 trial from 2018 - 2023 tested its efficacy against placebo in adults with AUD. Ibudilast was taken twice daily for 12 weeks vs placebo. Outcomes included heavy drinking days, drinks per day, and abstinent days. There was no significant difference between ibudilast and placebo on most outcomes. There were no significant effects on inflammation markers.